American Academy of Ophthalmology Meeting
American Academy of Ophthalmology Meeting
November 21, 2019
4 min watch
Save

VIDEO: Novel oral therapy drug safe, effective for wet AMD

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO —Twice daily dosing of oral AKST4290 over the course of 6 weeks improved visual acuity in patients with neovascular age-related macular degeneration, according to a presenter at the American Academy of Ophthalmology annual meeting.

“Further development of the drug is being planned [in] a randomized phase 2b study,” Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in Jacksonville, Florida, told Ocular Surgery News. “Subsequently, a phase 3 trial and discussions are underway for trials with diabetic macular edema and edema due to retinal vein inclusions.” – by Alaina Tedesco

Reference: Stewart MW. Visual outcomes in two open-label trials of oral AKST4290 in naïve and refractory nAMD. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Stewart reports being a consultant for Alkahest and Bayer Pharmaceuticals and receiving institutional research support from Allergan and Regeneron.